Our findings here that STAB offered considerable efficacy against both PDAC and NSCLC, coupled with our recent findings that a bsAb against S15 and TGF-b was able to meaningfully attenuate the immunosuppressive TME in TNBC 25, 26, suggests STAB may offer similar efficacy for TNBC as well as a wide hosts of other S15+ tumors. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.